Pro 2014-026 (Jianfeng Group's First Extraordinary Shareholders' Meeting in 2014)-1
Release time:
2020-08-05
证券代码：600668 证券简称：尖峰集团 公告编号：2014-026
债券简称：13尖峰01 债券代码：122227
浙江尖峰集团股份有限公司
关于召开2014年第一次临时股东大会的通知
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示：
l股东大会召开日期：2014年11月12日（星期三）下午
l股权登记日：2014年11月6日（星期四）
l是否提供网络投票：是
一、召开会议的基本情况
（一）股东大会届次：2014年第一次临时股东大会
（二）股东大会的召集人：本公司董事会
（三）会议召开的日期、时间
现场会议开始时间为2014年11月12日（星期三）下午14：30；
网络投票时间为2014年11月12日上午 9：30-11：30，下午13：00-15：00。
（四）会议的表决方式：本次会议采取现场投票与网络投票相结合的方式，公司将通过上海证券交易所交易系统向全体股东提供网络形式的投票平台，股东可以在网络投票时间内通过上述系统行使表决权。（投资者参加网络投票的操作流程详见附件二）同一次股东大会上的所有议案应采用相同的投票方式。
（五）现场会议地点：浙江省金华市婺江东路88号尖峰大厦三楼会议室。
（六）公司股票涉及融资融券业务、转融通业务，相关投资者应按照上交所发布的《关于融资融券业务试点涉及上市公司股东大会网络投票有关事项的通知》、《上海证券交易所上市公司股东大会网络投票实施细则（2012年修订）》以及转融通的有关规定执行。
二、会议审议事项
|
序号 |
议案内容 |
|
1.00 |
关于董事会任满换届的议案 |
|
1.01 |
选举蒋晓萌为第九届董事会董事 |
|
1.02 |
选举杜自弘为第九届董事会董事 |
|
1.03 |
选举虞建红为第九届董事会董事 |
|
1.04 |
选举黄速建为第九届董事会董事 |
|
1.05 |
选举吴光辉为第九届董事会董事 |
|
1.06 |
选举朱林明为第九届董事会董事 |
|
1.07 |
选举张余友为第九届董事会独立董事 |
|
1.08 |
选举史习民为第九届董事会独立董事 |
|
1.09 |
选举吴晓明为第九届董事会独立董事 |
|
2.00 |
关于监事会任满换届的议案 |
|
2.01 |
选举厉自强为第八届监事会监事 |
|
2.02 |
选举欧阳绍建为第八届监事会监事 |
|
2.03 |
选举原杰为第八届监事会监事 |
上述议案已分别经公司第八届董事会第19次会议、第七届监事会第13次会议审议通过，现一并提交股东大会审议，议案内容详见公司2014年10月28日披露于上海证券交易所公告网站的相关公告。
三、会议出席对象
（一）凡2014年11月6日（股权登记日）交易结束后在中国证券登记结算有限公司上海分公司登记在册的本公司股东及其授权委托人均可出席。
（二）本公司董事、监事和高级管理人员。
（三）本公司聘请的律师。
四、会议登记方法
（一）登记时间：2014年11月10日（星期一）上午 8：30—12：30，下午 13：00—17：00。
（二）登记地点：浙江省金华市婺江东路88号尖峰大厦董事会办公室306室。
（三）登记方式
1、个人股东亲自出席会议的，持本人身份证、证券账户卡办理登记；委托代理他人出席会议的，代理人持本人有效身份证件、股东授权委托书原件（见附件一）、委托人证券账户卡和委托人身份证复印件办理登记。
2、法人股东应由法定代表人或者法定代表人委托的代理人出席会议。法定代表人出席会议的，持本人身份证、证券账户卡、营业执照复印件办理登记；委托代理人出席会议的，代理人持本人身份证、法人股东单位的法定代表人依法出具的书面授权委托书原件（见附件一）、证券账户卡、营业执照复印件办理登记。
3、股东也可以通过信函或传真方式办理登记，信函以到达邮戳为准。以传真方式办理登记的，上述授权委托书原件应至少在 2014年11月12日（星期三）下午1：30前送交至公司董事会办公室。
五、其他事项
（一）会议联系方式
联系人：周恒斌
联系地址：浙江省金华市婺江东路88号尖峰大厦。
电话号码：0579-82324699
传真号码：0579-82324699
邮政编码：321000
（二）本次大会现场会预计半天，与会股东交通、食宿自理。
特此公告
浙江尖峰集团股份有限公司董事会
二〇一四年十月二十七日
l报备文件
提议召开本次股东大会的董事会决议
附件1:授权委托书格式
授权委托书
浙江尖峰集团股份有限公司：
兹委托 先生（女士）代表本单位（或本人）出席2014年11月 12日召开的贵公司2014年第一次临时股东大会，并代为行使表决权。
委托人签名（盖章）： 受托人签名：
委托人身份证号： 受托人身份证号：
委托人持股数： 委托人股东帐户号：
委托日期： 年 月 日
|
序号 |
议案内容 |
同意 |
反对 |
弃权 |
|
1.00 |
关于董事会任满换届的议案 |
|
|
|
|
1.01 |
选举蒋晓萌为第九届董事会董事 |
|
|
|
|
1.02 |
选举杜自弘为第九届董事会董事 |
|
|
More information Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution 2020 07-31 Spike New Drug Approved for Registration On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin) 2020 07-31 Spike New Drug Approved for Registration On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin) 2020 07-31 Contact Us 
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China 
Tel: +86-579-82326868 
Fax : +86-579-82324666 
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
|
